Restart Life Sciences Corp.
NMLSF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.03 | -0.00 | -11.97 |
| FCF Yield | 0.00% | -3.43% | -12,284.88% | -1.71% |
| EV / EBITDA | -15.03 | -12.92 | 0.35 | -2.44 |
| Quality | ||||
| ROIC | 115.45% | -259.52% | -257.38% | 129.96% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.38 | 0.29 | -83.06 | -0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 67.02% | -1,982.58% | -153.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.51 | 1.02 | 0.36 | -0.23 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |